Redefining the management of obesity: the evolutional shift from BMI-centric to holistic health centric

The introduction of incretin-based therapies, notably GLP-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1RAs, represents a new era in integrated metabolic care. Early GLP-1 RAs were available as once-daily or twice-daily injections and were initially supported primarily by glycaemic control and weight-loss data. More recently, the development of longer-acting, once-weekly formulations transformed the therapeutic landscape, offering improved convenience together with an expanding evidence base.